Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials

First published in Journal of Diabetes Science and Technology on 2022 Jul.
J Diabetes Sci Technol. 2022 Jul 11:19322968221105864. doi: 10.1177/19322968221105864. Online ahead of print.

Authors: Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O.

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

Understanding Biosimilar Insulins – Development, Manufacturing, and Clinical Trials

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.